# Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

> **NCT04706936** · PHASE1 · UNKNOWN · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 25 (estimated)

## Conditions studied

- Relapsed or Refractory Multiple Myeloma

## Interventions

- **BIOLOGICAL:** anti-BCMA CAR-T
- **DRUG:** Cyclophosphamid
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT04706936
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-01
- **Primary completion:** 2023-10
- **Final completion:** 2024-04
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2023-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04706936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04706936, "Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04706936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*